Low-Dose Naltrexone

Research on the effectiveness of Low-Dose Naltrexone (LDN) in fighting cancer – an evidence-based review

Low-dose naltrexone (LDN) – typically 1–5 mg daily, far below the 50 mg standard dose for opioid dependence – has attracted interest as a potential adjuvant in oncology. Over the last two decades researchers have proposed two main ways LDN might affect cancer: (1) modulation of the opioid growth factor (OGF) – OGF receptor (OGFr) axis to…

Read More
ECMISS

The Gavel Goes Digital: How ECMISS is Revolutionizing India’s Justice Delivery

Imagine a crucial court hearing postponed not because of a legal argument, but because a physical case file was lost in transit between offices. For decades, this was a frustrating reality in courtrooms across India. Mountains of paper, tedious manual processes, and inevitable delays created a justice system often perceived as slow and inaccessible. But…

Read More